The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth

Nisha C. Kakodkar, Radhika Peddinti, Morris Kletzel, Yufeng Tian, Lisa J. Guerrero, Samir D. Undevia, David Geary, Alexandre Chlenski, Qiwei Yang, Helen R. Salwen, Susan L. Cohn*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


The quinoxaline anti-tumor agent (R+)XK469 mediates its effects by topoisomerase IIB inhibition. This report describes a 14-year old with relapsed neuroblastoma who experienced disease stabilization for 14 months while receiving (R+)XK469 monotherapy. Due to this favorable response, laboratory studies were undertaken to determine efficacy in the preclinical setting. (R+)XK469 inhibited proliferation, caused G2 cell cycle arrest of neuroblastoma cells in vitro, and inhibited growth of neuroblastoma xenograft tumors. These preclinical results, coupled with the favorable clinical response, demonstrate that (R+)XK469 and similar anti-tumor agents may be effective in the treatment of high-risk neuroblastoma and warrant further testing.

Original languageEnglish (US)
Pages (from-to)164-167
Number of pages4
JournalPediatric Blood and Cancer
Issue number1
StatePublished - Jan 2011


  • Neuroblastoma
  • Phase I
  • Relapse
  • Topoisomerase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth'. Together they form a unique fingerprint.

Cite this